Prescriptions for weight loss drugs semaglutide and tirzepatide continued their steep climb through 2025, marking one of the fastest-growing trends in the prescription market. The medications, which mimic gut hormones that regulate appetite and blood sugar, have moved from diabetes care into mainstream obesity treatment. Demand has been fueled by strong clinical results and growing patient awareness of the drugs.